A Phase 1, Single Dose, Open Label, Randomized, 5-period Crossover Study To Evaluate The Relative Bioavailability And Food Effect On New Modified Release Tablet Of Pf-06650833 In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs PF 6650833 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 31 Jan 2018 Status changed from recruiting to completed.
- 21 Dec 2017 Planned End Date changed from 2 Jan 2018 to 1 Jan 2018.
- 16 Oct 2017 New trial record